Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Bioavailability of TGRX-326 in Healthy Subjects
NCT06304805Phase 1Completed
- Sponsor
- Shenzhen TargetRx
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deulorlatinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Shenzhen TargetRx. Primary endpoints: Plasma Maximum Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2023; status: completed.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06304805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304805.